Dexcom Faces US FDA Warning Amid Agency Review Of 15-Day Sensor

Warning Letter Is Temporary Setback But Unlikely To Result In Significant Market Share Loss, Analysts Say

 
• By Shubham Singh
  
FDA_Warning
The FDA’s 4 March warning letter highlighted deficiencies in Dexcom’s manufacturing processes and quality management systems at two key facilities • Source: Shutterstock

More from Diabetic Care

More from Compliance